FDA approves Bydureon, first once-weekly treatment for type 2 diabetesFDA has approved exenatide extended-release for injectable suspension (Bydureon, Amylin and Alkermes) ? the first once-weekly treatment for type 2 diabetes.From Ora Staff Reports...
Market authorization granted for Bydureon™ – the first once-weekly medication for Type 2 diabetesTyler GreerFuture Medicinal Chemistry